The tender offer, which is being extended to allow additional time for the consummation of Abbott's acquisition of Alere, could expire at the end of August.
The RealTime PCR instrument identifies AML patients with IDH2 mutations who can be treated with Celgene's Idhifa.
Abbott CEO Miles White said that he is confident that Abbott's acquisition of Alere will close as expected before the end of Q3.
About 63 million votes were in favor of the deal, representing more than 72.5 percent of all outstanding Alere shares as of the May 31 record date.
The firm said that the RealTime CMV test is the only commercially available cytomegalovirus that can amplify two select regions of the CMV genome.
Abbott CEO Miles White said that while Alere is a bit of a fixer upper, he is pleased to have a resolution to issues surrounding the proposed acquisition.
The firms also dropped their lawsuits against each other, and said they expect to complete the merger by the end of the third quarter.
The New York Stock Exchange gave Alere an additional six months to file its 2016 annual report, but it also said it could commence delisting proceedings at any time.
Researchers and companies move to develop blood-based tests for concussion, according to Scientific American.
The FDA granted Abbott Emergency Use Authorization for the assay in serum, plasma, and urine in November.
Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.
US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.
A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.
In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.